Stock Based Compensation

6 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 9 - Stock Based Compensation

The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model.

The expected volatility was determined with reference to the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted represents the period of time that the options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate in effect at the time of grant. The dividend yield is expected to be zero because historically the Company has not paid dividends on common stock.

The Company’s Xcede joint venture adopted an Equity Incentive Plan in 2013 which provides for, among other incentives, the granting of options to purchase shares in Xcede’s common stock to officers, directors, employees and consultants. The options granted generally vest over a three year period. The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model using assumptions generally consistent with those used for Company stock options. Because Xcede is not publicly traded, the expected volatility is estimated with reference to the average historical volatility of a group of publicly traded companies that are believed to have similar characteristics to Xcede.

As of March 31, 2019, DBM owned approximately 63% of Xcede’s outstanding Common Stock and Preferred Stock. No significant change in the Company’s position with respect to the ownership of Xcede’s stock occurred during the three months ended March 31, 2019.

Stock compensation expense for the three and six months ended March 31, 2019 and 2018 is as follows:

	Three Months Ended		Three Months Ended
	March 31, 2019		March 31, 2018
Stock Grants	$	91,000	$	91,000
Restricted Stock Grants		9,000		13,000
Option Grants		-		5,000
Employee Stock Purchase Plan		1,000		-
Subsidiary Option Grants		11,000		28,000
Total	$	112,000	$	137,000
	Six Months Ended		Six Months Ended
	March 31, 2019		March 31, 2018
Stock Grants	$	142,000	$	130,000
Restricted Stock Grants		24,000		26,000
Option Grants		-		17,000
Employee Stock Purchase Plan		2,000		1,000
Subsidiary Option Grants		22,000		56,000
Total	$	190,000	$	230,000

At March 31, 2019, there was approximately $32,000 in unrecognized stock compensation cost for Dynasil, which is expected to be recognized over a weighted average period of approximately thirteen months.

Restricted Stock Grants

A summary of restricted stock activity for the six months ended March 31, 2019 is presented below:

Restricted Stock Activity for the Six Months ended March 31, 2019	Shares			Weighted-Average Grant-Date Fair Value
Nonvested at September 30, 2018		60,000		$	1.61
Granted		-			-
Vested		(30,000	)		1.73
Cancelled		-			-
Nonvested and expected to vest at March 31, 2019		30,000		$	1.48

Stock Option Grants

During the six months ended March 31, 2019, no Dynasil stock options were granted. A summary of stock option activity for the six months ended March 31, 2019 is presented below:

	Options Outstanding			Weighted Average Exercise Price per Share		Weighted Average Remain Contractual Term (in Years)
Balance at September 30, 2018		160,537		$	2.01		0.93
Outstanding and exercisable at September 30, 2018		160,537		$	2.01		0.93
Granted		-			-
Exercised		-			-
Cancelled		(64,935	)		2.33
Balance at March 31, 2019		95,602		$	1.80		0.84
Outstanding and exercisable at March 31, 2019		95,602		$	1.80		0.84

Subsidiary Stock Option Grants

During the six months ended March 31, 2019, no Xcede stock options were granted. A summary of Xcede stock option activity for the six months ended March 31, 2019 is presented below:

	Options Outstanding		Weighted Average Exercise Price per Share		Weighted Average Remain Contractual Term (in Years)
Balance at September 30, 2018		1,300,956	$	1.00		7.31
Outstanding and exercisable at September 30, 2018		1,229,685		1.00		7.11
Granted		-		-
Exercised		-		-
Cancelled		-		-
Balance at March 31, 2019		1,300,956		1.00		6.60
Outstanding and exercisable at March 31, 2019		1,266,581	$	1.00		6.60

At March 31, 2019, the Company’s Xcede joint venture had approximately $21,000 of unrecognized stock compensation expense associated with stock options expected to be recognized over a period of six months.